Aflibercept Forecasted to Report Blockbuster Status from 2013


afliberceptAflibercept, also known as brand name Eyelea, has been recently touted as a 2013 blockbuster drug. With sales of Aflibercept in the United States thought to have surpassed 1.3 billion dollars in the 2013 calendar year, the pharmaceutical community has been optimistically awaiting final year end data. Marketed by Regeneron in the U.S., Eyelea {Aflibercept} has achieved an anticipated “blockbuster” status as an injectable treatment targeting patients with wet macular degeneration. The ideal every other month dosing schedule makes using Aflibercept easier and more tolerable for patients, as compared to the competitor Lucentis, which requires a monthly injection. In addition to being an effective treatment for age-related wet macular degeneration, Aflibercept was also approved in the United States in September 2012 for the treatment of macular edema following central retinal vein occlusion.

The United States is not the only country to embrace this efficacious product. The final quarter of 2013 brought the approval of Aflibercept in Japan for the treatment of macular edema after central retinal vein occlusion (CRVO).  Prior approval of Eyelea {Aflibercept} has been made by the European Commission, Asia and many Latin American countries for patients with post CRVO macular edema as well. Both wet age-related macular degeneration (AMD) and macular edema following CRVO are estimated to affect almost 70,000 citizens in the EU, 140,000 patients in Japan and more than two million Americans. The majority of patients suffering from these life altering vision conditions are over the age of forty. Most often treatment with Aflibercept is critical for helping these patient populations avoid a significant loss of vision as they age or to avoid total blindness.

Regeneron filed for a new indication approval for Aflibercept in the third quarter of 2013, seeking an approval of Eyelea for the treatment of vision loss related to diabetic macular edema. A decision regarding this request has yet to be rendered by the FDA. Dosing with Aflibercept commonly commences with a two milligram injection given in a healthcare setting every month (four weeks approximately) for the initial three months. After the first three month period the majority of patients continue on a dosing schedule of every other month, or every eight weeks. The two milligram dose remains the same. Adverse effects of Aflibercept are uncommon, and the majority of patients exhibit minimal side effects. The most common complaints from patients being dosed with Aflibercept include eye pain, floaters, cataract development and increased intraocular pressure. As a recombinant fusion protein Aflibercept is an ideal treatment for the vast number of patients suffering from vision impairment from eye related diseases like AMD and CRVO.

LGM Pharma provides Aflibercept CAS# 862111-32-8 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: